Finance

Lists
BMEA:NASDAQ
Biomea Fusion Inc
$0.61
-1.91%
(-0.012) 1D
$0.63
+2.65% (+0.016)
Pre-market
Closed: Nov 4, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BMEA...
Open
$0.62
High
$0.67
Low
$0.61
Mkt. cap
44.62M
Avg. vol.
2.57M
Volume
2.85K
52-wk high
$2.24
52-wk low
$0.56
EPS
-$0.50
Beta
-0.14
Shares outstanding
72.48M
No. of employees
37
Open
$0.62
High
$0.67
Low
$0.61
Mkt. cap
44.62M
Avg. vol.
2.57M
Volume
2.85K
52-wk high
$2.24
52-wk low
$0.56
EPS
-$0.50
Beta
-0.14
Shares outstanding
72.48M
No. of employees
37
News stories
From web sources and news partners
About Biomea Fusion Inc
CEO-
Employees37
Founded2017
HeadquartersSan Carlos, California, United States
SectorBiotechnology
Industry-
Websitebiomeafusion.com
Analyst ratings
Based on 6 analysts giving stock ratings to BMEA in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for BMEA in the last 3 months.
Highest
Current $0.61
$10.00 (+1,534.25%)
Average
$6.83 (+1,016.20%)
Lowest
$4.00 (+553.70%)
Analyst
Recommendation
Action
Price target
Projected
Date
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$4.00
+553.7%
10/29/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$7.00
+1,044%
10/14/2026
Joseph Pantginis
H.C. Wainwright
Buy
Maintained
$4.00
+553.7%
10/14/2026
Kumaraguru Raja
Brookline Capital Markets
Buy
Initiated
$10.00
+1,534.3%
10/07/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$7.00
+1,044%
08/06/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$9.00
+1,370.8%
08/06/2026
Anupam Rama
J.P. Morgan
Sell
Maintained
-
-
03/24/2026
Next call in 8 days
Fri, Nov 13, 10:00 PM
Fiscal period
Q3 2026
- / -$0.22
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
14.40M
8.12M
9.12M
9.14M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.20M
3.60M
3.65M
3.62M
Operating expense
18.60M
11.72M
12.77M
12.77M
Total operating expenses
18.60M
11.72M
12.77M
12.77M
Operating income
-18.60M
-11.72M
-12.77M
-12.77M
Other non operating income
-
19.86M
-581.00K
4.12M
EBT including unusual items
-16.41M
4.61M
-12.42M
-8.33M
EBT excluding unusual items
-14.20M
4.61M
-12.92M
-8.33M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-16.41M
4.61M
-12.42M
-8.33M
Net profit margin
-
-
-
-
Earnings per share
-0.24
-0.12
-0.17
-0.17
Interest and investment income
4.40M
-
430.00K
319.00K
Interest expense
-
-3.53M
-
-
Net interest expenses
4.40M
-3.53M
430.00K
319.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-18.17M
-11.67M
-12.73M
-12.75M
Gain or loss from assets sale
-
-
-510.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps